vs

Side-by-side financial comparison of LandBridge Co LLC (LB) and RIGEL PHARMACEUTICALS INC (RIGL). Click either name above to swap in a different company.

RIGEL PHARMACEUTICALS INC is the larger business by last-quarter revenue ($69.8M vs $56.8M, roughly 1.2× LandBridge Co LLC). RIGEL PHARMACEUTICALS INC runs the higher net margin — 384.0% vs 14.2%, a 369.8% gap on every dollar of revenue. On growth, LandBridge Co LLC posted the faster year-over-year revenue change (55.6% vs 21.2%). Over the past eight quarters, LandBridge Co LLC's revenue compounded faster (72.8% CAGR vs 53.7%).

Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing targeted small molecule therapies for autoimmune, inflammatory, and hematologic diseases. Its approved flagship product treats adult immune thrombocytopenia, with primary operations and core markets in the United States, addressing unmet medical needs for underserved patient groups.

LB vs RIGL — Head-to-Head

Bigger by revenue
RIGL
RIGL
1.2× larger
RIGL
$69.8M
$56.8M
LB
Growing faster (revenue YoY)
LB
LB
+34.4% gap
LB
55.6%
21.2%
RIGL
Higher net margin
RIGL
RIGL
369.8% more per $
RIGL
384.0%
14.2%
LB
Faster 2-yr revenue CAGR
LB
LB
Annualised
LB
72.8%
53.7%
RIGL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
LB
LB
RIGL
RIGL
Revenue
$56.8M
$69.8M
Net Profit
$8.1M
$268.1M
Gross Margin
91.5%
Operating Margin
60.0%
33.2%
Net Margin
14.2%
384.0%
Revenue YoY
55.6%
21.2%
Net Profit YoY
-83.7%
1769.2%
EPS (diluted)
$0.24
$14.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LB
LB
RIGL
RIGL
Q4 25
$56.8M
$69.8M
Q3 25
$50.8M
$69.5M
Q2 25
$47.5M
$101.7M
Q1 25
$44.0M
$53.3M
Q4 24
$36.5M
$57.6M
Q3 24
$28.5M
$55.3M
Q2 24
$26.0M
$36.8M
Q1 24
$19.0M
$29.5M
Net Profit
LB
LB
RIGL
RIGL
Q4 25
$8.1M
$268.1M
Q3 25
$8.1M
$27.9M
Q2 25
$7.5M
$59.6M
Q1 25
$6.5M
$11.4M
Q4 24
$49.3M
$14.3M
Q3 24
$2.7M
$12.4M
Q2 24
$-57.7M
$-1.0M
Q1 24
$10.8M
$-8.2M
Gross Margin
LB
LB
RIGL
RIGL
Q4 25
91.5%
Q3 25
93.2%
Q2 25
95.6%
Q1 25
91.7%
Q4 24
89.9%
Q3 24
85.5%
Q2 24
92.4%
Q1 24
93.1%
Operating Margin
LB
LB
RIGL
RIGL
Q4 25
60.0%
33.2%
Q3 25
60.8%
40.9%
Q2 25
60.0%
60.1%
Q1 25
57.0%
23.9%
Q4 24
49.4%
28.9%
Q3 24
11.2%
25.4%
Q2 24
-197.4%
1.2%
Q1 24
71.1%
-23.6%
Net Margin
LB
LB
RIGL
RIGL
Q4 25
14.2%
384.0%
Q3 25
15.9%
40.2%
Q2 25
15.8%
58.6%
Q1 25
14.7%
21.5%
Q4 24
135.2%
24.9%
Q3 24
9.3%
22.5%
Q2 24
-222.1%
-2.8%
Q1 24
56.7%
-27.9%
EPS (diluted)
LB
LB
RIGL
RIGL
Q4 25
$0.24
$14.11
Q3 25
$0.26
$1.46
Q2 25
$0.24
$3.28
Q1 25
$0.20
$0.63
Q4 24
$0.82
Q3 24
$-0.04
$0.70
Q2 24
$-0.06
Q1 24
$-0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LB
LB
RIGL
RIGL
Cash + ST InvestmentsLiquidity on hand
$30.7M
$155.0M
Total DebtLower is stronger
$570.7M
$52.5M
Stockholders' EquityBook value
$340.3M
$391.5M
Total Assets
$1.4B
$513.6M
Debt / EquityLower = less leverage
1.68×
0.13×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LB
LB
RIGL
RIGL
Q4 25
$30.7M
$155.0M
Q3 25
$28.3M
$137.1M
Q2 25
$20.3M
$108.4M
Q1 25
$14.9M
$77.1M
Q4 24
$37.0M
$77.3M
Q3 24
$14.4M
$61.1M
Q2 24
$24.6M
$49.1M
Q1 24
$49.5M
Total Debt
LB
LB
RIGL
RIGL
Q4 25
$570.7M
$52.5M
Q3 25
$366.1M
$60.0M
Q2 25
$370.9M
$60.0M
Q1 25
$375.5M
$60.0M
Q4 24
$385.5M
$60.0M
Q3 24
$242.4M
$60.0M
Q2 24
$360.8M
$60.0M
Q1 24
$60.0M
Stockholders' Equity
LB
LB
RIGL
RIGL
Q4 25
$340.3M
$391.5M
Q3 25
$272.0M
$117.6M
Q2 25
$266.4M
$81.9M
Q1 25
$217.0M
$18.6M
Q4 24
$211.8M
$3.3M
Q3 24
$97.2M
$-14.6M
Q2 24
$296.4M
$-29.9M
Q1 24
$162.3M
$-31.7M
Total Assets
LB
LB
RIGL
RIGL
Q4 25
$1.4B
$513.6M
Q3 25
$1.1B
$242.5M
Q2 25
$1.1B
$206.7M
Q1 25
$1.0B
$176.0M
Q4 24
$1.0B
$164.0M
Q3 24
$689.9M
$139.4M
Q2 24
$710.5M
$128.4M
Q1 24
$126.5M
Debt / Equity
LB
LB
RIGL
RIGL
Q4 25
1.68×
0.13×
Q3 25
1.35×
0.51×
Q2 25
1.39×
0.73×
Q1 25
1.73×
3.23×
Q4 24
1.82×
18.25×
Q3 24
2.49×
Q2 24
1.22×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LB
LB
RIGL
RIGL
Operating Cash FlowLast quarter
$126.3M
$22.0M
Free Cash FlowOCF − Capex
$122.0M
FCF MarginFCF / Revenue
214.9%
Capex IntensityCapex / Revenue
7.5%
Cash ConversionOCF / Net Profit
15.68×
0.08×
TTM Free Cash FlowTrailing 4 quarters
$207.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LB
LB
RIGL
RIGL
Q4 25
$126.3M
$22.0M
Q3 25
$34.9M
$24.0M
Q2 25
$37.3M
$30.5M
Q1 25
$15.9M
$-893.0K
Q4 24
$67.6M
$14.5M
Q3 24
$7.5M
$21.7M
Q2 24
$16.0M
$302.0K
Q1 24
$17.2M
$-5.0M
Free Cash Flow
LB
LB
RIGL
RIGL
Q4 25
$122.0M
Q3 25
$33.7M
Q2 25
$36.1M
Q1 25
$15.8M
Q4 24
$66.7M
Q3 24
$7.1M
Q2 24
$15.7M
Q1 24
$17.1M
FCF Margin
LB
LB
RIGL
RIGL
Q4 25
214.9%
Q3 25
66.3%
Q2 25
75.9%
Q1 25
36.0%
Q4 24
182.6%
Q3 24
25.1%
Q2 24
60.4%
Q1 24
90.1%
Capex Intensity
LB
LB
RIGL
RIGL
Q4 25
7.5%
Q3 25
2.3%
Q2 25
2.6%
Q1 25
0.2%
Q4 24
2.7%
Q3 24
1.1%
Q2 24
1.4%
Q1 24
0.5%
Cash Conversion
LB
LB
RIGL
RIGL
Q4 25
15.68×
0.08×
Q3 25
4.31×
0.86×
Q2 25
4.98×
0.51×
Q1 25
2.46×
-0.08×
Q4 24
1.37×
1.01×
Q3 24
2.80×
1.75×
Q2 24
Q1 24
1.60×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons